Efficacy comparison of medications approved for chronic weight management

Obesity

Volumn 23, Issue S1, 2015, Pages S4-S7

  Kumar, Rekha B ^a   Aronne, Louis J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE PLUS NALTREXONE; LIRAGLUTIDE; LORCASERIN; PHENTERMINE PLUS TOPIRAMATE; TETRAHYDROLIPSTATIN; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; BENZAZEPINE DERIVATIVE; FRUCTOSE; PHENTERMINE; TOPIRAMATE;

BODY MASS; CALORIC RESTRICTION; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; HORMONAL REGULATION; HUMAN; LIFESTYLE MODIFICATION; OBESITY; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; WEIGHT REDUCTION; ADULT; ANALOGS AND DERIVATIVES; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; FEMALE; PILOT STUDY;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BENZAZEPINES; BODY WEIGHT; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; FRUCTOSE; HUMANS; OBESITY; PHENTERMINE; PILOT PROJECTS; WEIGHT LOSS;

EID: 84928112309     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.21093     Document Type: Review

References (32)

1. http://www.ama-assn.org/ama/pub/news/news/2013/2013-06-18-new-ama-policies-annual-meeting.page. Accessed December 4, 2014.
2. Flegal KM, Carroll MD, Kit BK, Ogden CL,. Prevalence of obesity and trends in the distribution of body mass index among us adults, 1999-2010. JAMA. 2012; 307 (5): 291-497.
3. Bray G,. Medical consequences of obesity. J Clin Endocrinol Metab. 2004; 89 (6): 2583-2589.
4. Stein C, Colditz G,. The epidemic of obesity. J Clin Endocrinol Metab. 2004; 89 (6): 2522-2525.
5. Schmidt MI, Duncan BB,. Diabesity: An inflammatory metabolic condition. Clin Chem Lab Med. 2003; 41 (9); 1120-1130.
6. Silha JV, Kresk M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ,. Plasma resistin, adiponectin and leptin levels in leans and obese subjects: corrections with insulin resistance. Eur J Endocrinol. 2003; 149 (4); 331-335.
7. Trayhurn P, Wood S,. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004; 92 (3); 347-355.
8. Despres JP, Lemieux I, Prud'homme D,. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001; 322 (7288); 716-720.
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346 (6); 393-403.
10. Korner J, Aronne LJ,. The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest. 2003; 111 (5): 565-570.
11. Lowe M,. Self-regulation of energy intake in the prevention and treatment of obesity: is it feasible? Obes Res. 2003; 11 (Suppl); 44S-59S.
12. National Institutes of Health, National Heart, Lung, and Blood Institute. The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. 2002. NIH publication number 02-4084.
13. Flier JS, Maratos-Flier E,. Obesity and the hypothalamus: novel peptides for new pathways. Cell. 1998; 92 (4): 437-440.
14. Kumar RB, Aronne L,. Hypothalamic Inflammation: Is there evidence for human obesity? Curr Obes Rep. 2014; 3 (2): 242-247.
15. Li Z, Maglione M, Tu W, Majica W, Artebaurn D, Shugarman L, et al. Meta-analysis: Pharmacologic treatment of obesity. Ann Intern Med. 2005; 142 (7): 532-546.
16. Zhi J, Melia AT, Guerciolini R, Chung J, Kinberg J, Hauptman JB, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther. 1994; 56 (1); 82-85.
17. Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HP, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998; 352 (9123); 167-172.
18. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L,. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study. Diabetes Care. 2004; 27 (1): 155-161.
19. Gadde KM, Allison, DB, Ryan DH, Peterson CA, Troupin B, Schwiers ML, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011; 377 (9774): 1341-1352.
20. Gavey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012; 95 (2): 297-308.
21. Powell A, Aronne LJ, Apovian CM,. Phentermine plus topiramate for the treatment of obesity. Expert Rev. Endocrinol Metab. 2012; 7 (5): 503-510.
22. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363 (3): 245-256.
23. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997; 337 (9): 581-588.
24. Smith SR, Weissman NJ, Anderson CM, Sanchez M, Chuang E, Stubbe S, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363 (3): 245-256.
25. O'Neil PM, Smith SR, Weissman SM, Fidler MC, Sanchez M, Zhang J, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012; 20 (7): 1426-1436.
26. Greenway FL, Fujioka K, Plodkowski RA, Mudaliar S, Guttadauria M, Erickson J, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376 (9741): 595-605.
27. Makowski CT, Gwinn KM, Hurren KM,. Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obes Facts. 2011; 4 (6): 489-494.
28. Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011; 19 (1): 110-120.
29. Apovian CM, Aronne L, Rubino D, Still C, Wyatt H, Burns C, et al. COR-II Study Group A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013; 21 (5): 935-943.
30. Hollander P1, Gupta AK, Plodkowski R, Greenway F, Bays H, Burns C, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013; 36 (12): 4022-4029.
31. Smith SR, Fujioka K, Gupta AK, Billes SK, Burns C, Kim D, et al. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes Obes Metab. 2013; 15 (9): 863-866.
32. Smith SR, Garvey WT, Greenway F, Soliman W, Zhou S, Fain R, et al. Combination weight management (WM) pharmacotherapy with lorcaserin (LOR) and immediate release (IR) phentermine (phen). Obesity Week 2014: The American Society for Metabolic and Bariatric Surgery and the Obesity Society Joint Annual Scientific Meeting; November 4, 2014; Boston, MA. Abstract 2053P.